Coronary disease & ACSRandomised controlled trial
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
- Randomised controlled trial
- investigator-initiated
- multicentre
- double-blind
- placebo-controlled
- superiority
- 53 centres in China
- randomised by centre
Authors' conclusion
Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.
Study context
- Population
- Patients with STEMI undergoing primary PCI
- Participants
- 2,989 patients
- Comparison
- Low-dose postprocedural anticoagulation vs placebo
- Primary endpoint
- All-cause death, nonfatal MI, nonfatal stroke, definite stent thrombosis or urgent revascularization (any vessel)
- Follow-up
- 30 days
Primary result
As reported in the abstract
Hazard ratio
1.00
95% CI 0.63–1.57
Events by treatment group
PPA vs Placebo
HR 1.00 (95% CI 0.63–1.57)
Safety
| Outcome | PPA | Placebo | HR (95% CI) | |
|---|---|---|---|---|
| BARC 3–5 bleeding · 30 days | 0.5% | 0.7% | 0.74 (0.30–1.83) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. Circulation. Published 26 February 2024. doi:10.1161/circulationaha.123.067079
Summarised from the published abstract; every number is checked against it